Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific drug emicizumab (Hemlibra). The Company has also extended its range of SpyCatcher reagents to include Human IgM-FcSpyCatcher.
Bio-Rad’s comprehensive range of anti-biotherapeutic antibodies enables the development of robust and reliable bioanalytical assays against biologic drugs and is suitable for use in pharmacokinetic (PK) and anti-drug-antibody (ADA) assays for pertuzumab, guselkumab, canakinumab, belimumab, and emicizumab, facilitating therapeutic drug monitoring for innovator and biosimilar products.
The new Human IgM-FcSpyCatcher adds to Bio-Rad’s SpyCatcher collection — it is a unique reagent that allows researchers to rapidly switch antibody formats at the protein level, enabling spontaneous formation of pentameric and hexameric IgMs. Compatible with Bio-Rad’s recombinant HuCAL antibodies, the new SpyCatcher reagent has been successfully tested in ELISA, western blotting, and precipitation assays.
Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies is extensive; with 45 different specificities and more than 250 antibodies, we are providing greater flexibility for the development of highly selective and highly sensitive bioanalytical assays. With the addition of the new SpyCatcher protein, we are continuing to deliver new and innovative bioanalysis tools for both our custom and catalog antibody customers, driving advances in antibody drug discovery.”
Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad
The new antibodies and reagents are approved for in vitro research, with the anti-idiotypic antibodies also approved for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring.
New Insights into How B Cells Strategically Clone High-Affinity Antibodies